Form D · Pharmaceuticals

Ballantyne Therapeutics, Inc.

Charlotte, NC · CIK 0001645966

Offering snapshot reported Oct 22, 2015 · SEC filing

Reported sold
$565K
Offering amount: $800K
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 8, 2015
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$283K$565KJul 14, 2015: $400,000.00Jul 14, 2015Oct 22, 2015: $565,000.00Oct 22, 2015

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$400,000 → $565,000
  • Reported investors7 → 8

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 22, 2015Amendment$565,000$165,000vs Jul 14, 20158SEC filing
Jul 14, 2015Initial$400,000No comparison7SEC filing

Offering details

Securities
Debt
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-243626

Source: Form D, filed Oct 22, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Brian E. Doxtator Director
Simon Pedder Director
Donald R Reynolds Director
Michael Roberts Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
13850 Ballantyne Corporate Place Suite 500
Charlotte, NC, 28277